Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases

Prostate

Volumn 72, Issue 7, 2012, Pages 713-720

  Colombel, Marc ^a   Eaton, Colby L ^b   Hamdy, Freddy ^c   Ricci, Estelle ^a   Van Der Pluijm, Gabri ^d   Cecchini, Marco ^e   Mege Lechevallier, Florence ^a   Clezardin, Philippe ^f   Thalmann, George ^e  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF BERN   (Switzerland)

^f INSERM   (France)

Author keywords

alpha 2 integrin; alpha 6 integrin; bone metastasis; c met; immunohistochemistry; prostate cancer; survival

Indexed keywords

ALPHA2 INTEGRIN; ALPHA6 INTEGRIN; SCATTER FACTOR RECEPTOR;

ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER STEM CELL; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; SCORING SYSTEM; SURVIVAL TIME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; INTEGRIN ALPHA2; INTEGRIN ALPHA6; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; TUMOR MARKERS, BIOLOGICAL;

EID: 84860330623     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21473     Document Type: Article

References (28)

1. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK,. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011; 117 (13): 2883-2891.
2. Nieder C, Haukland E, Pawinski A, Dalhaug A,. Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases. BMC Urol 2010; 10: 23.
3. Guise T,. Examining the metastatic niche: Targeting the microenvironment. Semin Oncol 2010; 37 (Suppl 2): S2-14.
4. Lipton A,. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol 2010; 37 (Suppl 2): S15-29.
5. Coghlin C, Murray GI,. Current and emerging concepts in tumour metastasis. J Pathol 2010; 222 (1): 1-15.
6. Andreoiu M, Cheng L,. Multifocal prostate cancer: Biologic, prognostic, and therapeutic implications. Hum Pathol 2010; 41 (6): 781-793.
7. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT,. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117 (Pt 16): 3539-3545. (Pubitemid 39206394)
8. Gu G, Yuan J, Wills M, Kasper S,. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007; 67 (10): 4807-4815. (Pubitemid 46910189)
9. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ,. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65 (23): 10946-10951. (Pubitemid 41713363)
10. Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F, Thalman G,. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate 2010; 70 (8): 875-882.
11. Guzman-Ramirez N, Voller M, Wetterwald A, Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN, Cecchini MG,. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 2009; 69 (15): 1683-1693.
12. Bonkhoff H, Stein U, Remberger K,. Differential expression of alpha 6 and alpha 2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: Simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum Pathol 1993; 24 (3): 243-248. (Pubitemid 23086358)
13. Nagle RB, Knox JD, Wolf C, Bowden GT, Cress AE,. Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem Suppl 1994; 19: 232-237. (Pubitemid 24306473)
14. Colombel M, Gil DS, Radvanyi F, Buttyan R, Thiery JP, Chopin D,. Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms. Ann NY Acad Sci 1996; 784: 63-69.
15. Isaacs JT,. Apoptosis: Translating theory to therapy for prostate cancer. J Natl Cancer Inst 2000; 92 (17): 1367-1369.
16. van Leenders GJ, Schalken JA,. Stem cell differentiation within the human prostate epithelium: Implications for prostate carcinogenesis. BJU Int 2001; 88 (Suppl 2): 35-42. (Pubitemid 32955449)
17. Xue Y, Smedts F, Umbas R, Aalders TW, Debruyne FM, de la Rosette JJ, Schalken JA,. Changes in keratin expression during the development of benign prostatic hyperplasia. Eur Urol 1997; 32 (3): 332-338. (Pubitemid 27455442)
18. van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J,. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000; 80 (8): 1251-1258. (Pubitemid 30637065)
19. Ugolkov AV, Eisengart LJ, Luan C, Yang XJ,. Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 2010; 71 (1): 18-25.
20. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z,. The androgen receptor negatively regulates the expression of c-Met: Implications for a novel mechanism of prostate cancer progression. Cancer Res 2007; 67 (3): 967-975.
21. Knudsen BS, Miranti CK,. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression. J Cell Biochem 2006; 99 (2): 345-361. (Pubitemid 44435553)
22. Goel HL, Li J, Kogan S, Languino LR,. Integrins in prostate cancer progression. Endocr Relat Cancer 2008; 15 (3): 657-664.
23. Van Slambrouck S, Hilkens J, Bisoffi M, Steelant WF,. AsialoGM1 and integrin alpha2beta1 mediate prostate cancer progression. Int J Oncol 2009; 35 (4): 693-699.
24. Pontes-Junior J, Reis ST, Dall'oglio M, Neves de Oliveira LC, Cury J, Carvalho PA, Ribeiro-Filho LA, Moreira Leite KR, Srougi M,. Evaluation of the expression of integrins and cell adhesion molecules through tissue microarray in lymph node metastases of prostate cancer. J Carcinog 2009; 8: 3.
25. Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, Jiang WG,. Hepatocyte growth factor/scatter factor and prostate cancer: A review. Histol Histopathol 2005; 20 (4): 1339-1349. (Pubitemid 41489177)
26. Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, Stass SA, Jiang F,. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 2010; 90 (2): 234-244.
27. Gunia S, May M, Koch S, Dietel M, Erbersdobler A,. Expression of CD44s in incidental prostate cancer is more strongly associated with Gleason scores on subsequent radical prostatectomies than conventional prognostic parameters. Pathobiology 2009; 76 (6): 286-292.
28. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL,. CD44+CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008; 98 (4): 756-765. (Pubitemid 351272625)